Clinical application and progress of immune checkpoint inhibitors in biliary tract malignancies
10.3760/cma.j.cn115396-20240628-00200
- VernacularTitle:免疫检查点抑制剂在胆道恶性肿瘤中的临床应用及进展
- Author:
Huahu GUO
1
;
Xiaowei DANG
Author Information
1. 郑州大学第一附属医院肝胆胰外科 河南省肝胆胰疾病微创诊治工程研究中心 河南省卫生健康委员会普通外科（肝胆胰）疾病精准诊疗重点实验室，郑州 450052
- Keywords:
Immunosuppressive agents;
Biliary tract neoplasms;
Therapeutic uses;
Immunotherapy;
Clinical trial
- From:
International Journal of Surgery
2024;51(8):505-511
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract malignancies is a malignancy with insidious onset, low surgical resection rate, poor prognosis and unsatisfactory chemotherapy effects. With the continuous in-depth study, combined immunotherapy based on immune checkpoint inhibitors (ICIs) has gradually become an important direction for the treatment of biliary tract malignancies. Several clinical trials have conducted in-depth exploration of ICIs alone and in combination with first-line chemotherapy regimens or targeted drugs or double immunization regimens for biliary malignant tumors. The results show that ICIs monotherapy exhibits certain efficacy, albeit with significant variations in treatment outcomes. The combination of ICIs with first-line chemotherapy has now become the standard treatment protocol. Furthermore, the " triple-drug and quadruple-therapy regimen" involving ICIs in conjunction with chemotherapy and molecular targeted therapy holds promise as a potential new standard for BTC treatment. Additionally, dual immunotherapy combinations are gradually being implemented in clinical trials. In the present article, we provides an in-depth elaboration of the current status of clinical research on immune checkpoint inhibitors and their combination therapy in advanced biliary tract malignancies.
